Welcome to our dedicated page for Irhythm Technologies SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents from iRhythm Technologies don’t just recount earnings—they weave together reimbursement rulings, FDA study updates, and device-level production metrics that can shift Zio patch economics overnight. For investors, pulling the one sentence about CMS pricing from a 250-page 10-K or tracking day-to-day insider sales feels daunting.
Stock Titan solves that complexity. Our AI reads every iRhythm quarterly earnings report 10-Q filing, each iRhythm 8-K material event, and flags changes in plain English. Want iRhythm insider trading Form 4 transactions within minutes? You’ll see alerts the moment the Form 4 hits EDGAR, complete with contextual charts. Need an iRhythm annual report 10-K simplified or a quick iRhythm earnings report filing analysis? Our summaries spotlight Zio XT volume, average selling price shifts, and R&D spend so you can focus on decisions instead of footnotes.
Common investor questions are answered up front:
- iRhythm Form 4 insider transactions real-time
- iRhythm proxy statement executive compensation details
- understanding iRhythm SEC documents with AI
Beyond speed, our platform ties each disclosure to what truly moves the stock: hospital adoption rates, Medicare billing codes, and manufacturing scale. Drill into an iRhythm executive stock transactions Form 4 to see how trades align with new Zio AT rollouts, or compare segment margins across quarters without combing through PDFs. With real-time updates, complete filing coverage, and AI-powered plain-language explanations, iRhythm SEC filings explained simply becomes more than a promise—it’s the workflow that lets you act before the market does.
iRhythm Technologies, Inc. (IRTC) furnished an investor presentation as part of its shareholder engagement program. The presentation is included as Exhibit 99.1 to the report.
The materials in this disclosure are provided under Item 7.01 (Regulation FD) and are expressly stated as “furnished,” not “filed,” which means they are not subject to Section 18 liability and are not incorporated into other Securities Act or Exchange Act filings except by specific reference.
iRhythm Technologies (IRTC) reported an insider transaction by its President and CEO, who is also a Director. On 11/03/2025, the officer sold 14,059 shares of common stock at a price of $182.9367 per share.
The filing states the shares were sold to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units. Following the sale, the officer beneficially owns 164,979 shares, held directly.
iRhythm Technologies (IRTC) reported an insider transaction on Form 4. The company’s Chief Financial Officer sold 8,000 shares of common stock at $207.44 on 10/31/2025 pursuant to a Rule 10b5-1 trading plan established on November 14, 2024. Following the sale, the officer beneficially owns 26,470 shares directly and 100 shares indirectly through The Wilson Living Trust.
iRhythm Technologies (IRTC) reported strong top-line growth with narrowed losses. For the three months ended September 30, 2025, revenue was $192.9 million versus $147.5 million a year ago, and gross profit was $137.1 million versus $101.5 million. Loss from operations improved to $8.4 million from $50.3 million, and net loss was $5.2 million compared with $46.2 million. Net loss per share was $0.16 versus $1.48.
Year to date, revenue reached $538.2 million and operating cash flow was $54.7 million. The balance sheet showed cash and cash equivalents of $255.6 million and marketable securities of $309.6 million, with total assets of $995.2 million. Long‑term senior convertible notes stood at $648.8 million (carrying amount). Operating expenses reflected continued investment, including $21.0 million in R&D and $124.2 million in SG&A for the quarter. Shares outstanding were 32,219,143 as of October 23, 2025.
iRhythm Technologies (IRTC) furnished third‑quarter results and updated its executive severance program. The company furnished a press release for the quarter ended September 30, 2025 as Exhibit 99.1, noting it is furnished, not filed. The Board approved an amended and restated Executive Change in Control and Severance Policy covering Vice Presidents and above, including the CEO and other named officers.
Outside a change‑in‑control period, the CEO is eligible for 18 months of base salary, a 150% target bonus amount, and 18 months of COBRA; the CFO, Chief People Officer, and EVPs receive 12 months salary, 100% target bonus, and 12 months COBRA; SVPs and VPs receive 6 months salary, 50% target bonus, and 6 months COBRA. During the change‑in‑control period, the CEO terms increase to 24 months salary, 200% target bonus, 24 months COBRA, plus 100% acceleration of time‑based equity; CFO/Chief People Officer/EVPs: 18 months salary, 150% target bonus, 15 months COBRA, 100% equity acceleration; SVPs/VPs: 9 months salary, 75% target bonus, 9 months COBRA, 100% equity acceleration.
Daniel G. Wilson, Chief Financial Officer of iRhythm Technologies (IRTC), reported a sale of common stock executed under a Rule 10b5-1 trading plan. On 09/03/2025 Mr. Wilson disposed of 5,000 shares at $175 per share. After this transaction he beneficially owned 34,470 shares directly and an additional 100 shares indirectly through The Wilson Living Trust dated July 9, 2015, of which he is Trustee. The Form 4 was signed by an attorney-in-fact on 09/04/2025 and notes the 10b5-1 plan was established November 14, 2024.
Daniel G. Wilson, Chief Financial Officer of iRhythm Technologies, Inc. (IRTC), reported a sale of 737 shares of common stock on 09/02/2025 at a price of $167.28 per share. The filing states the shares were sold to cover tax withholding and remittance obligations related to the vesting of restricted stock units (RSUs). After the sale, Mr. Wilson directly beneficially owned 39,470 shares. The filing also discloses an indirect ownership of 100 shares held through The Wilson Living Trust dated July 9, 2015, of which he is trustee. The Form 4 was signed by an attorney-in-fact on 09/03/2025, reflecting a routine, compliance-focused disclosure of an insider transaction tied to RSU vesting.
iRhythm Technologies (IRTC) Form 144 reports a proposed sale of 5,000 common shares to occur on 09/03/2025 through Morgan Stanley Smith Barney LLC on Nasdaq with an aggregate market value of $875,000. The filing shows the 5,000 shares were originally granted as restricted stock in four tranches between 07/01/2020 and 12/31/2023, and the total equals the 5,000 shares listed for sale. The filer previously sold 3,737 shares in the past three months for aggregate proceeds of $573,285.36. The filing includes the required attestation that the seller is not aware of undisclosed material adverse information.
Shrishrimal Sumi, EVP and Chief Risk Officer of iRhythm Technologies (IRTC), reported a sale of company stock. The Form 4 shows a single non-derivative disposition of 653 shares of common stock on 08/22/2025 at a price of $167.12 per share, leaving the reporting person with 34,032 shares beneficially owned.
The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan established by the reporting person on May 23, 2025. The Form 4 was filed by one reporting person and signed by an attorney-in-fact.
iRhythm Technologies, Inc. (IRTC) Form 144 notice: An individual proposes to sell 653 shares of Common stock on or about 08/22/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing reports an aggregate market value of $109,129.36 and total shares outstanding of 32,127,763. The seller previously sold 1,608 shares on 06/02/2025 for gross proceeds of $225,457.68. Acquisition details for the 653 shares show three lots: 400 restricted shares acquired 06/01/2024, 129 ESPP shares 05/31/2023, and 124 ESPP shares 11/30/2022.
FAQ
What is the current stock price of Irhythm Technologies (IRTC)?
What is the market cap of Irhythm Technologies (IRTC)?
